Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$2.44 USD
-0.07 (-2.79%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $2.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Editas Medicine, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
EDIT 2.44 -0.07(-2.79%)
Will EDIT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EDIT
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Other News for EDIT
Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible
Editas Medicine Reaches Analyst Target Price
Editas Medicine (EDIT) Strengthens Despite FDA Division Shakeup
Gene editors steady despite latest leadership shake-up at FDA
JonesTrading Sticks to Their Hold Rating for Editas Medicine (EDIT)